The second patient was to receive paclitaxel with carboplatin/paclitaxel with cisplatin as an neoadjuvant chemotherapy regimen (100 points) for four cycles (19 points); his tumor size was T4 (0 points) and his hormone receptor status was negative (50 points). The gene discussed is NR4A1; the disease is neoplasm.